Literature DB >> 2069999

Kaposi's sarcoma unrelated to the acquired immunodeficiency syndrome.

M R Wick1.   

Abstract

Kaposi's sarcoma has achieved considerable notoriety in the past decade because of its association with the acquired immunodeficiency syndrome (AIDS). Nonetheless, this neoplasm continues to affect patients who do not have AIDS, and analysis of such cases may provide information that is useful in understanding the pathogenesis and treatment of Kaposi's sarcoma. Recent data indicate that non-AIDS-related Kaposi's sarcoma shows a predilection for individuals with the HLA-DR5 haplotype and that this genetic locus may affect immune function. In addition, other information suggests that infection with cytomegalovirus may represent the "trigger" for oncogenesis in patients with Kaposi's sarcoma. In view of the latter finding, therapies with such antiviral agents as zidovudine may be indicated in cases of non-AIDS-related Kaposi's sarcoma.

Entities:  

Mesh:

Year:  1991        PMID: 2069999     DOI: 10.1097/00001622-199104000-00021

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  3 in total

1.  Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Authors:  Zaklyah Kadry; Oscar Bronsther; David H Van Thiel; Parmjeet Randhawa; John J Fung; Thomas E Starzl
Journal:  Clin Transplant       Date:  1993-01-01       Impact factor: 2.863

2.  Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.

Authors:  F Bussolino; M Arese; G Montrucchio; L Barra; L Primo; R Benelli; F Sanavio; M Aglietta; D Ghigo; M R Rola-Pleszczynski
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

3.  Non-human immunodeficiency virus-related Kaposi's sarcoma of the oropharynx: a case report and review of the literature.

Authors:  Erika Crosetti; Giovanni Succo
Journal:  J Med Case Rep       Date:  2013-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.